Valeant seeks to become top 5 pharmaceutical company: CEO
(Reuters) - Valeant Pharmaceuticals International Inc VRX.TOVRX.N aims to crack the top-five ranks of drug companies by market capitalization by the end of 2016, Chief Executive Michael Pearson said on Tuesday.
Montreal, Quebec-based Valeant, which has a market cap of about $38.4 billion and sits among the top 15 pharmaceutical companies by that measure, would need to reach about $150 billion in market cap to crack the top five, Pearson said on a call with analysts and investors.
(Reporting by Rod Nickel in Winnipeg, Manitoba; Editing by Jeffrey Benkoe)
© Thomson Reuters 2015 All rights reserved.